Breaking Finance News

Maxim Group downgraded SciClone Pharma (NASDAQ:SCLN) from Buy to Hold in a statement released earlier today.

Having a price of $10.10, SciClone Pharma (NASDAQ:SCLN) traded 0.00% even on the day. With the last close down 5.94% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. SCLN has recorded a 50-day moving average of $11.09 and a 200-day moving average of $10.53. 115,673 shares of SCLN traded hands, down from an average trading volume of 457,435

Maxim Group has downgraded SciClone Pharma (NASDAQ:SCLN) from Buy to Hold in a statement released on 06/08/2017.

On 11/28/2016, Maxim Group released a statement on SciClone Pharma (NASDAQ:SCLN) upped the target price from $0.00 to $14.00 that suggested an upside of 0.37%.

Recent Performance Chart

SciClone Pharma (NASDAQ:SCLN)

SciClone Pharma has 52 week low of $8.55 and a 52 week high of $11.43 with a PE ratio of 13.75 and has a market capitalization of $0.

Brief Synopsis On SciClone Pharma (NASDAQ:SCLN)

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.